Key Highlights
- Acquisition of EDNA portfolio enhances AngelEye’s NICU technology.
- Nearly 250 hospital partners and technology at 7,000+ bedsides.
- AI-driven sensor technology identifies risks in neonates early.
- Improved outcomes through early detection and intervention.
Source: Business Wire
Notable Quotes
- “The acquisition of the EDNA portfolio is a pivotal moment for AngelEye. By combining our industry-leading footprint with EDNA’s portfolio, we gain the ability to extend our reach beyond engagement and into the realm of supporting clinical care.” — Christopher Rand, Chief Executive Officer at AngelEye Health
- “AngelEye’s acquisition of the EDNA portfolio is a game-changer, providing clinicians with essential tools to identify and stratify high-risk babies earlier.” — Kathi Randall, Consultant at NeuroNICU
- “AngelEye’s acquisition of the EDNA technology aligns with our mission, holding immense potential for making early detection assessments more widely accessible.” — Matthew McFarland, Vice President of Commercialization and Industry Relations at Nationwide Children’s Hospital
SoHC's Take
The acquisition of Enlighten Mobility’s EDNA portfolio by AngelEye Health represents a significant advancement in neonatal care, merging AI and sensor technology to address early risk detection in neonates. This strategic move not only solidifies AngelEye’s position as a leader in neonatal and pediatric family engagement services but also extends its capabilities into clinical care support. By integrating EDNA’s platform, AngelEye can provide clinicians with crucial tools for early intervention, potentially reducing long-term complications and improving patient outcomes. This acquisition is poised to revolutionize NICU care, demonstrating the transformative impact of technology in healthcare.
